Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of β-lactamase-mediated cefiderocol resistance

11 Jul 2022

Abstract excerpt

BACKGROUND: Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability toward β-lactamases, including carbapenemases, achieved by combining structural moieties of two clinically efficient cephalosporins, ceftazidime and cefepime. Consequently, cefiderocol represents a treatment alternative for infections caused by MDR Gram-negatives. OBJECTIVES: To study the role of cefiderocol on resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Nosocomial Infections in ICU

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35815680
DOI: 10.1093/jac/dkac221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of β-lactamase-mediated cefiderocol resistancePMID 35815680Read ↗

Evolution of β-lactamase mediated cefiderocol resistanceSemantic proximity Read ↗

In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.Semantic proximity Read ↗

Effects of different carbapenemase and siderophore production on cefiderocol susceptibility in Klebsiella pneumoniae.Semantic proximity Read ↗

Delaying cefiderocol resistance development in NDM-producing <i>Enterobacter cloacae</i> complex by combining cefiderocol with aztreonam <i>in vitro</i>Semantic proximity Read ↗

Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure In Vitro.Semantic proximity Read ↗

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitorsSemantic proximity Read ↗

Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosaSemantic proximity Read ↗

Defining Baseline Mechanisms of Cefiderocol Resistance in the EnterobacteralesSemantic proximity Read ↗

Influence of acquired β-lactamases on the evolution of spontaneous carbapenem resistance in Escherichia coli.Semantic proximity Read ↗

Cefiderocol “under siege”? Understanding the rise of NDM-mediated resistance to novel agentsSemantic proximity Read ↗

In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosaSemantic proximity Read ↗

Extrachromosomal resistance in gram-negative organisms: the evolution of beta-lactamase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.